Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377178 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL8377968 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1119584 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL15106754 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10878033 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2093730 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL11321046 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL6745183 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL3092648 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1119457 | 0.98 | NR5A1 (0.62) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| CN-112154167-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-12-29 | — | — | CN | disclosed |
| CN-111315828-A | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020021969-A1 | COMPOSITION, CURED PRODUCT, OPTICAL FILTER, AND PRODUCTION METHOD FOR CURED PRODUCT | 株式会社ADEKA | 2020-01-30 | — | — | WO | disclosed |
| CN-108456157-A | 1- substituted benzoyl -4- fatty acyl group amino carbamide derivative, preparation method and the purposes as antibacterials | 中国医学科学院药物研究所 | 2018-08-28 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-0753505-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5591714-A | TREATING VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTIONS WITH GLYCOPEPTIDE ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 1997-01-07 | — | — | US | disclosed |
| US-5554474-A | ELECTROGRAPHY | EASTMAN KODAK COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| US-5536878-A | HYDROGEN ACCEPTOR | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| EP-0690360-A2 | Polyurethane biasable transfer members | EASTMAN KODAK COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5382690-A | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5360577-A | MIXTURE OF OPTICALLY ACTIVE OXAZOLINE COMPOUND AND A LIQUID CRYSTALLINE CARRIER | HOFFMANN-LA ROCHE INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0588060-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0534258-A1 | Chiral oxazolines as dopants for liquid crystals mixtures | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-31 | — | — | EP | disclosed |
| EP-0435503-A1 | Improvements in or relating to gylcopeptide derivatives | ELI LILLY AND COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NR5A1 675/4885LTA4H 3093/4885TP53 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.